Tarao K, Shimizu A, Harada M, Ohkawa S, Tamai S, Ito Y, Kuni Y, Takemiya S, Okamoto T
Department of Internal Medicine, Kanagawa Cancer Center, Yokohama, Japan.
Jpn J Med. 1990 Jul-Aug;29(4):373-8. doi: 10.2169/internalmedicine1962.29.373.
Bromodeoxyuridine (BrdU) labeling indices (LI) of liver biopsied specimens from 27 control liver cirrhosis patients (control LC) without hepatocellular carcinoma (HCC), 26 cirrhotic patients with HCC, and from 6 control subjects were examined using an in vitro BrdU labeling technique. The mean BrdU LI +/- S.E. of HCC cancerous portion, HCC non-cancerous cirrhotic portion, control LC, and control subjects were 6.6 +/- 0.8%, 2.7 +/- 0.3%, 1.7 +/- 0.3% and 0.25 +/- 0.09%, respectively. Interestingly, there was a significant difference (p less than 0.025) between the non-cancerous LC portion and control LC. While 25 of 26 non-cancerous LC portion of HCC patients were in the high LI group (greater than or equal to 1.4%), 15 of 27 in the control LC were in the low LI group (less than 1.4%) (p less than 0.001). Of the 12 control LC with high LI, 6 developed HCC within 2 years, whereas only one of the 15 control LC with low LI developed HCC (p less than 0.05). In conclusion, HCC may develop in cirrhotic patients with high DNA synthetic potency.
采用体外溴脱氧尿苷（BrdU）标记技术，检测了27例无肝细胞癌（HCC）的对照肝硬化患者（对照LC）、26例合并HCC的肝硬化患者以及6例对照受试者肝脏活检标本的BrdU标记指数（LI）。HCC癌组织、HCC非癌性肝硬化组织、对照LC和对照受试者的平均BrdU LI±标准误分别为6.6±0.8%、2.7±0.3%、1.7±0.3%和0.25±0.09%。有趣的是，非癌性LC组织与对照LC之间存在显著差异（p<0.025）。HCC患者的26个非癌性LC组织中有25个属于高LI组（≥1.4%），而对照LC的27个中有15个属于低LI组（<1.4%）（p<0.001）。12个高LI的对照LC中有6个在2年内发生了HCC，而15个低LI的对照LC中只有1个发生了HCC（p<0.05）。总之，DNA合成能力高的肝硬化患者可能发生HCC。
